There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Airsculpt Technologies, Inc. (AIRS – Research Report) and Cara Therapeutics (CARA – Research Report) with bullish sentiments. Ascendis Pharma (ASND) Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma today and set a price target of $117.00. The company's shares closed last Friday at $102.18, close to its 52-week low of $101.04. According to TipRanks.com, Moussatos ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.9% and a 24.8% success rate.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-airsculpt-technologies-inc-airs-and-cara-therapeutics-cara?utm_source=advfn.com&utm_medium=referral
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Cara Therapeutics Charts.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Cara Therapeutics Charts.